BRCA1 and neoplasm: Since (epi)genetic reactivation of BRCA1/2 function has been shown to be the main mechanism of platinum resistance in BRCA1/2-mutated tumors, it is plausible that some of these patients might have already developed BRCA-proficient, and therefore PARPi-resistant, tumor clones as a result of a first-line treatment.32